Evaluating Neurodevelopmental Consequences of Perinatal Exposure to Antiretroviral Drugs: Current Challenges and New Approaches
- 11 September 2019
- journal article
- review article
- Published by Springer Nature in Journal of Neuroimmune Pharmacology
- Vol. 16 (1) , 113-129
Abstract
As antiretroviral therapy (ART) becomes increasingly affordable and accessible to women of childbearing age across the globe, the number of children who are exposed to Human Immunodeficiency Viruses (HIV) but remain uninfected is on the rise, almost all of whom were also exposed to ART perinatally. Although ART has successfully aided in the decline of mother-to-child-transmission of HIV, the long-term effects of in utero exposure to ART on fetal and postnatal neurodevelopment remain unclear. Evaluating the safety and efficacy of therapeutic drugs for pregnant women is a challenge due to the historic limitations on their inclusion in clinical trials and the dynamic physiological states during pregnancy that can alter the pharmacokinetics of drug metabolism and fetal drug exposure. Thus, much of our data on the potential consequences of ART drugs on the developing nervous system comes from preclinical animal models and clinical observational studies. In this review, we will discuss the current state of knowledge and existing approaches to investigate whether ART affects fetal brain development, and describe novel human stem cell-based strategies that may provide additional information to better predict the impact of specific drugs on the human central nervous system. Approaches to evaluate the impact of drugs on the developing brain. Dysregulation of the developing nervous system can lead to long-lasting changes. Integration of data from animal models, clinical observations, and cell culture studies is needed to predict the safety of therapeutic antiretroviral drugs during pregnancy. New approaches include human induced pluripotent stem cell (iPSC)-based 2D and 3D models of neuronal networks and brain regions, as well as single cell profiling in response to drug exposure.Keywords
Funding Information
- National Institute of Neurological Disorders and Stroke (R35NS097370)
- National Institute of Allergy and Infectious Diseases (U19AI131130)
- National Institute of Mental Health ((R21MH118037)
This publication has 125 references indexed in Scilit:
- Prevalence of Congenital Anomalies in Infants With In Utero Exposure to AntiretroviralsThe Pediatric Infectious Disease Journal, 2012
- HIV-1 Antiretroviral Drug TherapyCold Spring Harbor Perspectives in Medicine, 2012
- The Human Brain in a Dish: The Promise of iPSC-Derived NeuronsCell, 2011
- Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patientsNeurology, 2011
- Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohortAIDS, 2011
- HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapyNeurology, 2010
- Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohortNeurology, 2010
- Duration, Pattern of Breastfeeding and Postnatal Transmission of HIV: Pooled Analysis of Individual Data from West and South African CohortsPLOS ONE, 2009
- Normal Development of Brain CircuitsNeuropsychopharmacology, 2009
- Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performanceAIDS, 2009